Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Juul Sues FDA, Accuses It Deliberately Withheld Scientific Materials Related To Sales Ban

Published 21/09/2022, 12:26
Updated 21/09/2022, 13:11
© Reuters. Juul Sues FDA, Accuses It Deliberately Withheld Scientific Materials Related To Sales Ban

  • E-cigarette maker Juul Labs Inc, backed by Altria Group Inc (NYSE: NYSE:MO), filed a complaint accusing the FDA's refusal to disclose documents supporting its banning order on the company's products.
  • In June, the agency ordered Juul to stop selling and distributing all its products marketed in the U.S., saying the company's products played a disproportionate role in the rise in youth vaping.
  • In a Reuters report, the complaint noted that the FDA invoked the "widely abused" deliberative process privilege to improperly withhold scientific materials that are "central" to understanding the basis for the sales ban.
  • In the report, Juul said the materials would show whether the FDA conducted a legally required risk/benefit analysis of its products, including claims they help smokers quit cigarettes, and whether the agency's reasoning was scientifically sound.
  • "The public deserves a complete picture of the scientific facts behind one of the agency's most controversial and closely scrutinized decisions in recent years," Juul said.
  • In July, FDA administratively stayed the marketing denial order," the agency's tobacco division wrote in a tweet. "The agency has determined that scientific issues unique to the Juul application warrant additional review."
  • Juul Labs agreed to pay $438.5 million to 34 states and territories in September to sort out a two-year bipartisan investigation into its marketing and sales practices.
  • Price Action: MO shares closed at $43.00 on Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.